In a four-month landmark analysis of ECOG
Phase III study E4A03, patients who continued on treatment of REVLIMID plus low-dose dexamethasone (Rd) achieved a two-year overall survival rate of 93 percent.
study findings demonstrate that the Oncotype DX DCIS Score reveals the underlying biology of DCIS and can help individualize treatment decisions for this pre-invasive type of breast cancer.
We are excited by the ECOG
partnership opportunity to develop a unique multidisciplinary organization positioned to study the entire cancer care path from early detection through management of advanced disease," says Mitchell D.
Data presented in this subanalysis demonstrated that Nexavar is effective for the treatment of HCC in patients from the Asia-Pacific region (n=150) with a safety profile consistent with the overall study population, independent of baseline ECOG
performance status and the presence or absence of macroscopic vascular invasion (MVI) and/or extrahepatic spread (EHS).
Because of the strong one-year survival data seen in the ECOG
trial, we think there is a need to continue to evaluate novel treatment options.
The independent review showed a similar magnitude of benefit relative to the initial results presented by ECOG
at the American Society of Clinical Oncology annual meeting in 2005.
All evaluable patients had baseline ECOG
scores of less than 2 and the median number of prior chemotherapies was 5.
SWOG Action Based on Results from ECOG
Phase III Study (E4A03)
We would like to thank ECOG
investigators for their work on this study, which showed Avastin provided a significant clinical benefit for advanced breast cancer patients in the trial," said Hal Barron, M.
In addition, closer cooperation between the two large cooperative groups, SWOG and ECOG
, will provide important benefits to patients.
He co-chaired the Developmental Therapeutics Committee of ECOG
and chairs the Special Conferences Committee of the AACR (2002-).
Patient performance status as per the ECOG
score were: score 0 in 1 patient (10%); score 1 in 6 patients (60%); score 2 in 2 patients (20%); and score 3 in 1 patient (10%).